Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/11/2793781/0/en/Cogent-Biosciences-Announces-Positive-Data-from-Ongoing-Phase-2-APEX-Trial-Evaluating-Bezuclastinib-in-Patients-with-Advanced-Systemic-Mastocytosis-AdvSM.html

56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose

Read more at globenewswire.com

Related news for (COGT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.